TriangleNCT00241358 · OUTCOME
Proportion of Recipients Who Experience Chronic GVHD (Recipient Only)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Between Day +100 and +365 post-transplant
What was measured
-Incidence and severity of chronic GVHD will be assessed based on the Seattle criteria
Analysis population: Only 28 recipients received stem cell products on study. The others were not eligible due to relapse/progression, poor donor collection, receiving non-AMD3100 mobilized cells, or death before day +100.
Groups in this outcome
Subcutaneous (SC) Treatment Plan - Donor
* Day 1: Mobilization with 240 mcg/kg SC AMD3100 and leukopheresis * If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3.
Recipients
* Conditioning Regimen * Cyclophosphamide 60mg/kg/day on Days -3 and -2 * TBI 550cGy on Day -1 * GVHD prophylaxis \*Cyclosporin 3.0mg/kg/day beginning on Day -1 then tapered through Day +100 * PBSC transplant on Day 0
Intravenous (IV) Treatment Plan - Donor
* Day -3: Mobilization with 80-480 mcg/kg/day IV AMD3100 and PK analysis * Day 1: Mobilization with 240 mcg/kg/day SC AMD3100 and leukopheresis * If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3.
| Group | Source count |
|---|---|
| Subcutaneous (SC) Treatment Plan - Donor | 0 |
| Recipients | 28 |
| Intravenous (IV) Treatment Plan - Donor | 0 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Recipients | 10 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG001
- value
- 10
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 28
- group Id
- OG002
- value
- 0
- units
- Participants
- description
- -Incidence and severity of chronic GVHD will be assessed based on the Seattle criteria
- groups
- description
- * Day 1: Mobilization with 240 mcg/kg SC AMD3100 and leukopheresis * If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3.
- id
- OG000
- title
- Subcutaneous (SC) Treatment Plan - Donor
- description
- * Conditioning Regimen * Cyclophosphamide 60mg/kg/day on Days -3 and -2 * TBI 550cGy on Day -1 * GVHD prophylaxis \*Cyclosporin 3.0mg/kg/day beginning on Day -1 then tapered through Day +100 * PBSC transplant on Day 0
- id
- OG001
- title
- Recipients
- description
- * Day -3: Mobilization with 80-480 mcg/kg/day IV AMD3100 and PK analysis * Day 1: Mobilization with 240 mcg/kg/day SC AMD3100 and leukopheresis * If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3.
- id
- OG002
- title
- Intravenous (IV) Treatment Plan - Donor
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Only 28 recipients received stem cell products on study. The others were not eligible due to relapse/progression, poor donor collection, receiving non-AMD3100 mobilized cells, or death before day +100.
- reporting Status
- POSTED
- time Frame
- Between Day +100 and +365 post-transplant
- title
- Proportion of Recipients Who Experience Chronic GVHD (Recipient Only)
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice